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Abstract
The nonstructural protein 3 (NS3) from the hepatitis C virus processes the non-structural region of the viral precursor
polyprotein in infected hepatic cells. The NS3 protease activity has been considered a target for drug development since its
identification two decades ago. Although specific inhibitors have been approved for clinical therapy very recently,
resistance-associated mutations have already been reported for those drugs, compromising their long-term efficacy.
Therefore, there is an urgent need for new anti-HCV agents with low susceptibility to resistance-associated mutations.
Regarding NS3 protease, two strategies have been followed: competitive inhibitors blocking the active site and allosteric
inhibitors blocking the binding of the accessory viral protein NS4A. In this work we exploit the intrinsic Zn+2-regulated
plasticity of the protease to identify a new type of allosteric inhibitors. In the absence of Zn+2, the NS3 protease adopts a
partially-folded inactive conformation. We found ligands binding to the Zn+2-free NS3 protease, trap the inactive protein,
and block the viral life cycle. The efficacy of these compounds has been confirmed in replicon cell assays. Importantly, direct
calorimetric assays reveal a low impact of known resistance-associated mutations, and enzymatic assays provide a direct
evidence of their inhibitory activity. They constitute new low molecular-weight scaffolds for further optimization and
provide several advantages: 1) new inhibition mechanism simultaneously blocking substrate and cofactor interactions in a
non-competitive fashion, appropriate for combination therapy; 2) low impact of known resistance-associated mutations; 3)
inhibition of NS4A binding, thus blocking its several effects on NS3 protease.
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Introduction
The hepatitis C virus (HCV) infection is a worldwide health
problem. HCV infected people amount to more than 200 million,
80% of them becoming chronic patients, and many progressing to
cirrhosis and hepatocellular carcinoma. In Europe and the United
States chronic hepatitis C is the most common chronic liver
disease and it is the main cause of liver transplantation. The
hepatitis C infection presents serious drawbacks: 1) difficult
diagnosis, asymptomatic infection and lack of preventive vaccines
due to the reduced immune response against the virus; 2) severe
side-effects and high cost of the current treatment leading to
reduced patience adherence; 3) high natural genetic variability and
appearance of drug resistance facilitated by the high replication
rate together with the lack of proofreading capability in the viral
RNA polymerase. Therefore, there is an urgent need for new
specific, potent anti-HCV agents with reduced susceptibility to
mutations in the target.
NS3 protease is a 20 KDa serine protease structurally
homologous to other extracellular serine proteases, such as trypsin
and chymotrypsin, located at the N-terminal domain of the NS3
protein. Homologous extracellular proteases present disulfide
bridges stabilizing the molecular structure. However, as expected
for an intracellular protease working under reducing conditions,
NS3 does not contain disulfide bridges, but a Zn+2 ion tetra-
coordinated by three cysteine residues and a histidine residue
located in its C-terminal domain [1–4] (Figure 1). The Zn+2 ion is
required for the hydrolytic activity, since its removal leads to
inactivation. However, it is located very far (.20 Å) from the
catalytic triad (H57/D81/S139 in NS3 numbering) to be directly
involved in catalysis. Consequently, the Zn+2 ion is considered to
have a structural, stabilizing role equivalent to that of the disulfide
bonds present in other serine proteases. NS3 protease function
additionally requires the binding of the viral nonstructural protein
4A (NS4A) [5–8], which provides further structural stabilization
through restructuring the N-terminal domain of NS3 protease,
enhancement of the proteolytic activity by changing the config-
uration of the catalytic triad of NS3 protease, and appropriate
cellular membrane localization through a highly hydrophobic
terminal NS4A portion. Both NS4A and Zn+2 enhance the
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catalytic efficiency of the protease. While NS3 protease presents
some basal level of proteolytic activity in the absence of NS4A, it
has no activity in the absence of Zn+2.
Since its identification, the NS3 protease has been considered a
pharmacological target for drug discovery. Although a broad
variety of competitive inhibitors has been developed, very few of
them have entered clinical trials. Very recently, two protease
inhibitors have been approved by the FDA for therapeutic
treatment [9,10]. However, resistance mutations causing an
efficacy reduction for these two drugs have already been identified
[11–13]. Some efforts have been directed at developing allosteric
inhibitors that directly block the NS4A binding site [14–16].
A detailed biophysical characterization of the NS3 protease
suggested a considerable global conformational change upon Zn+2
binding involving mainly the tertiary structure of the protein
[17,18]. Disruption of the NS3-Zn+2 interaction leads to signifi-
cant unfolding into a conformation resembling a molten globule
and maintaining some residual structure. The conformational
change will move apart the catalytic residues, since H57 and D81
are located in the N-terminal domain, and S139 in the C-terminal
domain, leading to enzyme inactivation. Therefore, in the absence
of Zn+2, NS3 protease is mostly unstructured and can be
considered an intrinsically (partially) disordered protein that folds
upon binding to its Zn+2 cofactor. The conformational stability of
the Zn+2-free NS3 protease is very low (Gibbs energy of
stabilization at 20uC of 0.4 kcal/mol), and fully unfolded protein
(35%) coexists with partly unstructured-folded protein (65%) at
that temperature. Thus, Zn+2 binding provides most of the
stabilization energy in the Zn+2-bound NS3 protease. Therefore,
regarding the Zn+2 interaction, three structurally, energetically
and functionally distinguishable conformational states can be
considered: the Zn+2-bound folded native protein, the Zn+2-free
unstructured partly folded protein, and the completely unfolded
protein. NS3 protease being an intracellular enzyme, its structural
molecular integrity is regulated by the free Zn+2 pool inside the
cell. There is some controversy about the concentration of free
Zn+2 within the cell, but normal levels are in the low nanomolar
range [19]. As soon as the internal concentration of free Zn+2
slightly increases, regulatory processes are initiated in order to
remove any Zn+2 excess [20–22]. According to this accepted
hypothesis, cells do not operate with a significant pool of free Zn+2
and cellular Zn+2 homeostasis and occupancy are under kinetic
control. In addition, it has been shown that, similarly to most Zn+2
enzymes, the interaction of NS3 protease with Zn+2 exhibits very
slow kinetics, with a small kinetic association constant [23].
The complex allosterically modulated conformational landscape
of the NS3 protease should not be regarded as peculiar. In a broad
sense, allostery consists in the modulation of protein conforma-
tional equilibrium and function by ligand binding. Since any
ligand binding preferentially to a given conformational state will
stabilize it and increase its population, the population of the
different conformational states of a protein will depend on their
interaction with certain ligands. In this way, ligands concentration
may control protein function through modulation of the protein
conformational landscape. The pH dependency of binding
interactions and enzymatic activities in proteins is perhaps the
most pervasive type of allosteric control: proton binding to certain
functional groups modulates the population of different protein
conformational and functional states.
In this work, we exploit the complex conformational landscape
of the NS3 protease for developing new allosteric inhibitors. The
existence of an inactive partially-folded highly-populated confor-
mation for NS3 protease in the absence of Zn+2, significantly
dissimilar to the active native state, led us to the establish the
following hypothesis: because the population of Zn+2-free inactive
partially-folded state is physiologically relevant, specific ligand
Figure 1. Structure of NS3 protease bound to its two cofactors, Zn+2 and NS4A. Crystallographic structure of the protease domain (N-
terminal domain of NS3 protein) from the hepatitis C virus (PDB code: 1JXP). The two cofactors are shown: NS4A protein (pink) and zinc (yellow). The
catalytic triad (H57, D81, S139) and the zinc coordination residues (C97, C99, C145, H149) are shown in blue sticks. Dissociation of the NS4A protein in
the N-terminal domain leads to partial unfolding of that domain and slight distortion of the catalytic triad spatial configuration. Dissociation of the
zinc atom in the C-terminal domain causes global unfolding in both domains.
doi:10.1371/journal.pone.0069773.g001
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binding will stabilize it and trap the enzyme into that conforma-
tion, preventing the activating effect of the interaction with its
Zn+2 and NS4A cofactors, thus, effectively inhibiting the catalytic
activity in an allosteric fashion. The tightly regulated low
intracellular Zn+2 pool may contribute to the efficacy of this new
allosteric inhibition mechanism.
Inhibiting the enzyme by shifting the conformational equilib-
rium from a properly folded Zn+2-bound enzyme to a partially
folded Zn+2-free inactive enzyme as a result of ligand binding must
be energetically costly and kinetically very unfavourable (large
activation energy). But, interfering with and disrupting the timing
of the processes leading to an active enzyme may be plausible.
Thus, in addition to equilibrium interaction parameters, kinetic
considerations should be taken into account for the different
processes involved: protein synthesis and folding, Zn+2 interaction,
intracellular Zn+2 concentration. Because all these processes are
tightly coupled, the trapping of the protein into an inactive
conformational state due to ligand binding together with a low
intracellular Zn+2 concentration may represent a considerable
barrier towards producing an active enzyme.
To identify compounds exhibiting this behaviour, an experi-
mental ligand screening was performed following NS3 protease
stabilization under conditions where the inactive partially-folded
conformation is predominantly populated (in the presence of a
saturating concentration of ethylene diamine tetraacetic acid,
EDTA, a Zn+2-chelating agent). A set of compounds were selected
based on the stabilizing effect induced on NS3 protease against
thermal denaturation. Their potency as HCV-replication inhibi-
tors and their cytotoxicity were evaluated in cell assays. These
inhibitors show a new mechanism of action in which substrate and
cofactor interactions are blocked in a non-competitive fashion,
show a low binding affinity reduction against resistance-associated
NS3 protease mutant variants, and could be used in combination
therapy with the current approved clinical inhibitors.
Materials and Methods
Chemical Library
The compounds were supplied dissolved in dimethyl sulfoxide
(DMSO) 100% at a concentration of 4 mM (Prestwick Chemical,
USA). According to the manufacturer, the compounds are FDA-
approved drugs selected for their high chemical and pharmaco-
logical diversity. In addition, information on their bioavailability,
as well as toxicity and safety, in humans is available.
NS3 Protease
The N-terminal domain from full-length NS3 protein corre-
sponding to NS3 protease was expressed and purified as described
elsewhere [17,18]. The isolated protease domain exhibits similar
properties (enzymatic activity, inhibition constants, and allosteric
activation mechanism) to those of the full-length protein [24].
Cells and Replicon System
The highly permissive cell clone Huh 7-Lunet, as well as Huh 7
cells containing subgenomic HCV replicons I389luc-ubi-neo/
NS3-39/5.1 (Huh 5-2), I377NS3-39/wt (Huh 9-13) or I389/hygro-
ubi-NS3-3/5.1 (a kind gift from Dr. V. Lohmann and Dr. R.
Bartenschlager) have been described recently [25-28]. Cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco,
Belgium) supplemented with 10% heat-inactivated fetal bovine
serum (PAN-Biotech GmbH, Germany), 1X non-essential amino
acids (Gibco), 100 IU/mL penicillin (Gibco), 100 mg/mL strepto-
mycin (Gibco), and 250 mg/mL geneticin (G418; Gibco).
Experimental Screening
A non-native inactive partially-folded conformation of the NS3
protease is populated in the absence of Zn+2. Although this state is
highly unstructured, it maintains a significant amount of residual
structure and may be stabilized by ligands. Ligands binding to and
stabilizing this inactive conformation will act as allosteric inhibitors
trapping the NS3 protease into an inactive conformation.
Ligands for NS3 protease have been identified by an
experimental screening procedure based on a thermal-shift assay
similar to that employed previously for identifying small-molecule
compounds acting as Helicobacter pylori flavodoxin inhibitors and
human phenylalanine hydroxylase chaperones [29,30]. Ligands
targeting the inactive partially-folded NS3 protease state have
been identified as those compounds inducing a stabilizing effect in
NS3 protease against thermal denaturation in the absence of Zn+2.
The protein unfolding transition was monitored by following ANS
(8-anilino 1-naphthalene sulfonic acid; Sigma-Aldrich) emission
fluorescence, which greatly increases when it binds to hydrophobic
regions in the protein exposed to the solvent upon thermal
unfolding.
Ligand-induced NS3 stabilization was assessed by monitoring
the thermal denaturation of recombinant pure NS3 protease in a
FluoDia T70 High Temperature Fluorescence Microplate Reader
(Photon Technology International, UK). Protein-ligand solutions
(100 mL) were dispensed into 96-well microplates (ThermoFast 96
skirted plates, Thermo Scientific) and overlaid with 20 mL of
mineral oil to prevent evaporation. Protein solutions contained
2 mM NS3 protease in 100 mM sodium acetate, 2 mM EDTA,
pH 5, and 100 mM ANS. Ligands dissolved in DMSO were added
at 100 mM (with a final 2.5% residual concentration of DMSO) to
microplates containing the protein solutions and incubated at
25uC for 30 minutes before loading into the microplate reader.
Control experiments with NS3 protease samples with/without
DMSO and/or Zn+2 were routinely performed in each micro-
plate. Thermal denaturation was monitored by following the
increase in ANS fluorescence intensity associated with protein
unfolding (lexc = 395 and lem = 500 nm, where lexc is the
excitation wavelength and lem is the emission wavelength
27).
Unfolding curves were registered from 25uC to 75uC in 1uC steps.
The system was allowed to equilibrate at each temperature for 1
minute before each fluorescence acquisition. In practice, this
represents an operational heating rate of 0.25uC/min approxi-
mately.
Although in the absence of Zn+2 NS3 retains some structure, it
shows very low stability against thermal denaturation [18].
Approximately 40% of the molecules are completely unfolded at
25uC. Therefore, the native baseline in the pre-unfolding region is
absent in the thermal denaturation assays. The mid-transition
temperature can be operationally defined as the temperature for
maximal slope in the unfolding curve or, alternatively, the
temperature at which half of the maximal change in the signal is
achieved. The absence of the native pre-unfolding baseline makes
somewhat difficult the evaluation of the mid-transition tempera-
ture following the second criterion. Therefore, hits were identified
as those compounds shifting the temperature for maximal slope
towards higher temperatures, compared to the internal controls in
each microplate.
Antiviral Assay with Huh 5-2 Cells
Antiviral assays for assessing the efficacy of the selected
compounds were performed as described in literature [23–28].
Briefly, Huh 5-2 cells were seeded at a density of 5?103 cells per
well in a tissue culture-treated white 96-well view plate (Techno
Plastic Products AG, Switzerland) in complete DMEM supple-
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mented with 250 mg/mL G418. After incubation for 24 hours at
37uC medium was removed and 2-fold serial dilutions in complete
DMEM (without G418) of the test compounds were added in a
total volume of 100 mL. After 3 days of incubation at 37uC cell
culture medium was removed and luciferase activity was
determined using the Bright-GloTM Luciferase Assay System
(Promega Corporation, The Netherlands). The luciferase signal
was measured using a Synergy HT Multimode Reader (BioTek
Instruments Inc, USA). The 50% effective concentration (EC50)
was defined as the concentration of compound that reduced the
luciferase signal by 50%.
Cytostatic Assay
Cytostatic assays for assessing the cell viability of the selected
compounds were performed as described in literature [25–28].
Briefly, Huh 5-2 were seeded at a density of 5?103 cells per well of
a 96-well plate in complete DMEM with the appropriate
concentrations of G418. Serial dilutions of the test compounds
in complete DMEM (without G418) were added 24 hours after
seeding. Cells were allowed to proliferate for 3 days at 37uC, after
which the cell number was determined by CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega Corporation).
The 50% cytostatic concentration (CC50) was defined as the
concentration that inhibited the proliferation of exponentially
growing cells by 50%.
Isothermal Titration Calorimetry (ITC) Assay
Ligand binding to NS3 protease was determined with a high-
sensitivity isothermal titration VP-ITC microcalorimeter (Micro-
Cal, USA). Protein samples and reference solutions were properly
degassed and carefully loaded into the cells to avoid bubble
formation during stirring. Experiments were performed with
freshly prepared buffer-exchanged protein solutions, at 25uC in
100 mM sodium acetate, 2 mM EDTA, pH 5. NS3 protease
20 mM solution in the calorimetric cell was titrated with
compound 300 mM solution. Control experiments were performed
under the same experimental conditions, except for the presence
of zinc (no addition of EDTA). The heat evolved after each ligand
injection was obtained from the integral of the calorimetric signal.
The heat due to the binding reaction was obtained as the
difference between the reaction heat and the corresponding heat
of dilution, the latter estimated as a constant heat throughout the
experiment, and included as an adjustable parameter in the
analysis. The association constant (Ka) and the enthalpy change
(DH) were obtained through non-linear regression of experimental
data to a model for a protein with a single ligand binding site. Data
were analyzed using software developed in our laboratory
implemented in Origin 7 (OriginLab, USA).
NS3 protease wild-type, pseudo-wild-type (containing the
inactivating mutation S139A) and several variants containing
drug-resistance associated mutations (R155K, R155Q, A156T,
and D168A) were employed for determining the impact of these
mutations on the interaction of the selected compounds with the
protein (change in dissociation constant).
In vitro Enzymatic Inhibition Assay
The inhibition effect of the selected compounds on NS3
protease was assessed employing the FRET substrate Ac-Asp-Glu-
Asp(EDANS)-Glu-Glu-Abu-L-lactoyl-Ser-Lys(DABCYL)-NH2
(Bachem AG, Switzerland) [31]. A solution of purified NS3
protease at 1 mM final concentration (buffer sodium acetate pH 5)
was treated sequentially adding: 1) EDTA at 100 mM final
concentration; 2) compound at 0 or 25 mM final concentration
(compound stock solutions are 10 mM in 100% DMSO; therefore,
the same volume of DMSO was added to the control samples
without compounds); 3) Zn+2 at either 200, 100, or 50 mM final
concentration. Each addition of EDTA, compound and Zn+2 was
followed by 30-minute incubation at room temperature. Finally,
substrate was added at 4 mM final concentration for initiating the
hydrolysis reaction. Fluorescence intensity was measured in
triplicates using a Synergy HT Multimode Reader (BioTek
Instruments Inc, USA) using 380 nm and 500 nm for excitation
and emission wavelengths, respectively. NS3 protease activity was
determined as the initial slope of the curve. The quotient between
the activity in the presence (25 mM) and the absence of a given
compound provides the percentage of inhibition.
Results
Identification of NS3 Protease Ligands by Experimental
Screening
The presence of ANS and DMSO might induce an additional
minor destabilization, but the observed unfolding traces are in
agreement with those obtained in the absence of DMSO and ANS
by monitoring the intrinsic tryptophan fluorescence in NS3
protease [18]. Besides, the minor destabilizing effect induced by
ANS and DMSO will be the same for all samples, including the
controls.
Although the Zn+2-free NS3 protease retains some structure, it
shows very low stability against thermal denaturation. Approxi-
mately 40% of the molecules are unfolded at 25uC. Therefore, the
native baseline in the pre-unfolding region is absent in the thermal
denaturation assays (Figure 2). Compounds binding to the NS3
protease are identified as those compounds stabilizing the protein
against thermal unfolding, i.e. those compounds increasing the
mid-transition temperature. The mid-transition temperature has
been defined as the temperature for maximal slope in the
unfolding curve. Therefore, hits were identified as those
compounds shifting the temperature for maximal slope to higher
temperatures, compared to the internal controls in each micro-
plate (Figures 2 and 3).
Antiviral Activity of Selected Compounds in HCV
Subgenomic Replicon Cells
Compounds selected in the experimental screening are ligands
targeting the inactive partially-folded Zn+2-free NS3 protease
conformation. Therefore, those compounds will act as allosteric
inhibitors stabilizing and trapping the NS3 protease into an
inactive conformation.
In order to test if this hypothesis is correct and the compounds
effectively inhibit viral replication, the potency of these compounds
was assessed by in vitro HCV replication assays with genotype 1b
Con1 HCV subgenomic replicons (Huh 5-2). From the 17
compounds identified from the thermal up-shift screening, 7 of
them inhibited HCV replicon replication (measured as luciferase
signal) in a dose-dependent manner with EC50 lower than
100 mM (Table 1, Figure 4). The estimated EC50 values for these
compounds ranged from nanomolar to micromolar. The anti-
HCV activity was not the result of a cytostatic effect, since the
CC50 values for these compounds were significantly higher than
the EC50 values.
Binding of Selected Compounds to Wild Type and Drug-
resistance NS3 Protease Variants by ITC
The dissociation constants for the interaction between NS3
protease wild-type, pseudo-wild-type (S139A) and drug-resistance
associated variants with the selected compounds are summarized
Allosteric Inhibitors of NS3 Protease
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in Table 2. The results indicate that these compounds interact
specifically with the Zn+2-free NS3 protease conformation. All
NS3 variants tested bind these compounds with similar affinity,
with a dissociation constant (Kd) in the micromolar range (Figure 5)
Figure 2. Experimental screening for ligands binding to the Zn+2-free NS3 protease. Thermal denaturation curves of Zn+2-free NS3
protease followed by ANS fluorescence in the presence of different compounds (100 mM sodium acetate, pH 5, 2 mM EDTA). Inset: Thermal
denaturation of Zn+2-free NS3 protease followed by tryptophan intrinsic fluorescence (average energy of spectra). The unfolding transition restricted
to the temperature range accessible in the microplate fluorescence reader for the library screening is indicated in closed squares for comparison.
doi:10.1371/journal.pone.0069773.g002
Figure 3. Compounds selected from experimental screening and exhibiting antiviral activity in cell assays. Chemical structures of the
selected compounds by experimental screening were further tested in cell-based, calorimetric and enzymatic assays.
doi:10.1371/journal.pone.0069773.g003
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and Kd ratios no larger than 5 (compared to the pseudo-wild-type
NS3). Therefore, the impact of the currently known resistance-
associated mutations is small. Control experiments in the presence
of Zn+2 (no EDTA added) indicated the compounds do not bind to
the Zn+2-bound protein.
Inhibition of NS3 Protease
The direct inhibition of NS3 protease was tested with the
selected compounds. The protocol consisted of: 1) removing Zn+2
from the enzyme by adding EDTA (to obtain Zn+2-free NS3
protease); 2) adding a given inhibitor compound (to the Zn+2-free
NS3 protease); 3) adding Zn+2 to the enzyme; 4) and initiating the
catalytic reaction by adding the substrate. According to the
dissociation constant for the EDTA-Zn+2 at pH 5 (Kd of 0.8 nM
[14]), and the total concentrations of Zn+2 (50, 100 and 200 mM)
and EDTA (100 mM) employed in the inhibition assay, the
concentration of free Zn+2 for each case is 0.8 nM, 0.9 mM and
0.1 mM, covering 5 orders of magnitude.
At a given concentration of Zn+2, the presence of the selected
compounds at 25 mM concentration reduces the catalytic activity
of the NS3 protease (Figure 6). The percentage of inhibition (ratio
between the initial rates with and without compound) depends on
Zn+2 concentration. At normal intracellular concentration there is
significant inhibition, whereas at high concentration inhibition
capability is significantly reduced (Figure 6). Similar results were
obtained with all the selected compounds.
Discussion
Drug development against hepatitis C virus targeting the NS3
protease with competitive inhibitors has proven difficult mainly
due to a very shallow substrate binding site. Binding to a solvent-
exposed binding site does not benefit enough from the solvent
entropy gain originated by water molecules release upon binding,
and rely in the optimization of different intermolecular interac-
tions (hydrogen bonds, van der Waals and electrostatic interac-
tions) for achieving sufficient affinity. Thus, despite the vast
amount of knowledge gathered on serine proteases during the last
several decades, drugs targeting the NS3 protease consisting of
competitive inhibitors have only been recently approved. As
expected in the case of a virus with high replication rate and lack
of proofreading ability, resistance mutations have been already
reported for these drugs [11–13]. Targeting the NS3-NS4A
interaction has also experienced limited success. Therefore, there
is an urgent need for new approaches and strategies for drug
development against HCV.
The biophysical characterization of a protein target provides
invaluable information on: 1) structural and functional features of
the protein target; 2) potential strategies and methodologies for
ligand binding screening; 3) criteria for optimizing ligand binding
affinity and specificity. The NS3 protease is a small serine protease
with a complex conformational landscape modulated by its two
natural cofactors, NS4A and Zn+2. In the absence of its two
natural cofactors, it is unable to fold into its active conformation.
Zn+2 binding is responsible for 60% of structural organization and
at least 80% of the stabilization energy of the native folded
conformation [15,18]. Therefore, NS3 protease folding is strongly
coupled to the interaction with a Zn+2 ion, and in the absence of
Zn+2 the NS3 protease adopts a partially folded inactive
conformation with some residual structure. This conformation is
relevant in vivo considering that NS3 is synthesized intracellularly
within the viral polyprotein, and must be processed and folded
appropriately into the active conformation in an environment
experiencing Zn+2 stress, where intracellular Zn+2 concentration is
very low, in the nanomolar range or lower, and it is tightly,
kinetically regulated [19–22]. In fact, the association kinetics for
Zn+2 binding to the NS3 protease is considerably slow. In
particular, an apparent association rate constant, kobs, of around
0.014 s21 can be estimated at pH 7.5 [23]. If a pseudo-first order
association can be assumed, would yield a kon ,0.0014 mM21s21.
Under physiological conditions, the intracellular zinc concentra-
tion is in the low nanomolar range (or even lower) and, therefore,
the rate of association would be lower than 0.000014 s21.
Moreover, through refolding experiments of NS3 protease by
Figure 4. Inhibition of HCV replicon in cell assays. Evaluation of potency and cytotoxicity of the selected compounds in cell assays. HCV
replicon replication rate (white bars) and cell survival (closed squares) were assessed in cell culture at increasing compound concentration to
determine EC50 and CC50. For compounds 1 and 3 assays with lower concentrations were performed in order to reliably determine the EC50. *UTC:
untreated controls.
doi:10.1371/journal.pone.0069773.g004
Table 1. Evaluation of potency and cytotoxicity of the
selected compounds in cell assays.
EC50 (mM)a CC50 (mM)b CC50/EC50
Compound 1 0.03 .120 .4000
Compound 2 10 80 8
Compound 3 0.03 8 240
Compound 5 60 .120 .2
Compound 6 20 .120 .6
Compound 7 2 .120 .60
Compound 8 4 60 15
aEC50, effective concentration 50%;
bCC50, cytotoxic concentration 50%.
Relative error in the parameters is 15%.
doi:10.1371/journal.pone.0069773.t001
Allosteric Inhibitors of NS3 Protease
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e69773
measuring the catalytic activity in the presence of substrate and
increasing concentrations of zinc, an apparent dissociation
constant of about 1 mM for the NS3-zinc interaction can be
estimated [1]. In addition, by performing ITC experiments, a
dissociation constant of 0.5 mM for the NS3-zinc interaction was
estimated at pH 5 [17].
Consequently, the Zn+2-free conformation of the NS3 protease
is structurally and energetically distinguishable from the folded
active conformation and represents a new drug target. Any ligand
specifically binding to that alternative conformation will stabilize
and trap such inactive conformation, thus allosterically inhibiting
the enzyme.
An experimental screening based on ligand-induced stabiliza-
tion against thermal denaturation (thermal up-shift) provided
several candidate compounds. This methodology allowed selecting
small molecules able to bind to the Zn+2-free conformation of the
NS3 protease. Despite some common structural features (e.g.
presence of aromatic rings), there is low structural similarity
between these compounds. The targeted conformation of the
protein (Zn+2-free NS3 protease) is highly flexible due to structure
loss and can be considered as an ensemble of energetically
indistinguishable conformational microstates. Different ligands
may bind to different structural motifs in the partly unfolded
protein.
Figure 5. Interaction with Zn+2-free NS3 protease. Calorimetric assays for determining the binding affinity of selected compounds to the NS3
protease. Upper plots: thermograms representing the thermal power required for maintaining the calorimetric cell at constant temperature; lower
plots: binding isotherm representing the heat associated with each injection as a function of the advance of the binding process ([ligand]Total/
[protein]Total). The continuous line corresponds to the non-linear regression fitting analysis considering a single binding site model.
doi:10.1371/journal.pone.0069773.g005
Table 2. Dissociation constants for selected compounds binding to drug-resistance-associated NS3 protease variants (25uC,
100 mM sodium acetate, 2 mM EDTA, pH 5).
Kd (mM)
WT S139Aa S139A/R155K S139A/R155Q S139A/A156T S139A/D168A
Compound 1 1.9 6.5 5.3 2.6
Compound 2 29 8.4 23 21 11
Compound 3 2.5
Compound 5 1.7 5.5 5.9 32 27 8.5
Compound 6 40 24 61 23 45 36
Compound 7 16 5.7 16 4.2 5.8 6.5
Compound 8 31 34 9.2 42 22 16
aThe inactive S139A mutant represents the pseudo-wild-type, behaving similarly to wild-type (WT) NS3 protease in terms of structural stability, substrate binding affinity
and NS4A activation.
Relative error in the parameters is 15%.
doi:10.1371/journal.pone.0069773.t002
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Replicon cell assays were performed in order to validate the
initial experimental screening. Some of the identified compounds
were able to inhibit the replication of the replicon system (Figure 3,
Table 1). In these in vitro assays, additional processes besides direct
enzyme-inhibitor interaction are taking place: internalization and
membrane pump efflux of compounds, synthesis and processing of
the viral polyprotein (in particular, full-length NS3), viral
replication cycle, and hepatic cell metabolism, among others.
Calorimetric titrations were conducted to assess the direct
enzyme-inhibitor interaction. The compounds were able to bind to
the Zn+2-free NS3 protease with moderate-to-high binding
affinities (dissociation constants in the micromolar range or lower)
(Table 2). There is no need for very high affinities for these
compounds, because they will not compete with the substrate or
the allosteric activator NS4A for their respective binding site.
There is no direct correlation between dissociation constant (Kd)
and EC50 values. However, the dissociation constant is deter-
mined from biophysical assays using purified protein and reflects
the direct interaction of each compound with the Zn+2-free
conformation of the NS3 protease, while the EC50 is determined
from cell-based assays and reflects the inhibition activity on the
replicon system involving several coupled processes as mentioned
before (protein synthesis, protein folding, ligand binding, ligand
availability, etc.).
The selected compounds will hinder the conformational
transition between two different conformations, one largely
unfolded and another native-like folded, in an allosteric fashion,
and, therefore, these compounds will block simultaneously the
binding of substrate and NS4A. In addition, the impact of
reported resistance mutations associated to current clinical NS3
protease inhibitors is quite small (not larger than 5-fold). Again,
this is due to the fact these selected compounds are directed
towards a different target (Zn+2-free NS3 protease conformation)
compared to the current clinical competitive inhibitors (Zn+2-
bound NS3 protease). There might be other mutations affecting
the binding of these compounds, but they must be different from
the already reported resistance mutations.
Continuous enzymatic assays using a FRET substrate provided
direct evidence for the inhibition activity of the selected
compounds on NS3 protease. The inhibition assays were
performed at different Zn+2 concentrations, from values under
typical intracellular Zn+2 concentrations to very high values. Zn+2
promotes folding of the enzyme towards the folded active
conformation, whereas the selected compounds trap the enzyme
into the inactive partially folded conformation. As expected, as a
result of the competing action exhibited by the compounds and
Zn+2 (though they are not competitive inhibitors), the percentage
of inhibition decreases with Zn+2 concentration.
Traditionally, allosteric effectors (activators or inhibitors) have
been considered to exert their action on well-defined structures,
modulating the populations of the different conformational states
according to their intrinsic binding affinities and their effective
concentrations. The selected compounds described in this work
bind specifically to a conformational state of the target that is
largely unstructured with some residual structure, preventing the
conformational transition towards the active folded conformation
(Figure 7). In fact, there is no requirement for residual structure for
a given target to constitute a drug target, since the ligand binding
may induce the structural rearrangement, at least locally, and
block the target by preventing further interactions. In addition, the
targeted conformational state may be transiently populated, as
long as it is accessible enough for efficient ligand binding.
Therefore, this work highlights the importance of alternative
partially-folded conformational states, even transiently populated,
in pharmacological targets for drug design and development
strategy. The approach shown here for the NS3 protease might be
of outstanding relevance bearing in mind the large number of
metalloproteins (in which the structural integrity of the protein is
strongly coupled to the interaction with a metal ion characterized
by low bioavailability) and of intrinsically (partially) disordered
proteins in genomes.
The advantages of these new allosteric inhibitors can be
summarized as follows: 1) new inhibition mechanism in which
substrate and cofactor interactions are simultaneously blocked in a
non-competitive fashion; 2) new low molecular weight scaffolds for
further optimization (regarding affinity, specificity, toxicity,…); 3)
reduced impact of known resistance-associated mutations, showing
a small affinity reduction for drug-resistant NS3 protease variants;
4) inhibition of NS4A binding, blocking its several effects on NS3
protease (e.g. activity enhancement, intracellular membrane
Figure 6. In vitro enzymatic inhibition of NS3 protease. (Left panel) Fluorescence intensity measured as a function of time (wavelengths of
380 nm and 500 nm for excitation and emission, respectively) for the substrate catalysis by NS3 protease in the absence (open squares) or presence
of compound 1 at 25 mM (closed squares), in sodium acetate pH 5, 0.8 nM free Zn+2 concentration. (Right panel) NS3 protease activity was
determined as the initial slope of the curves. The percentage of activity is calculated as the quotient between the activity of NS3 protease in the
presence (25 mM) and the absence of a given compound (compound 1, closed squares; compound 5, open squares).
doi:10.1371/journal.pone.0069773.g006
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localization within the replicative complex); and 5) possibility of
combination therapy (highly-active antiviral therapy) together with
the current approved clinical inhibitors.
Conclusions
New allosteric inhibitors of the NS3 protease have been
identified by exploiting the fairly complex conformational
landscape of NS3 protease. The intrinsic plasticity of the enzyme
coupled to the tight regulation of Zn+2 intracellular concentration
at very low levels give rise to an inactive partially-folded
conformational state in the absence of Zn+2. This alternative
conformational state can be considered a new drug target, and
compounds binding to it will stabilize and trap the protein into
that inactive partially-folded state, therefore, blocking the viral life
cycle (Figure 7). The efficacy and cytotoxicity of these compounds
have been evaluated in cell assays, and they show promising
characteristics: low molecular weight, moderate-to-high potency
(from micromolar to nanomolar EC50) and moderate-to-low
cytotoxicity. Besides, these inhibitors show a new mechanism of
action, and could be combined with current competitive clinical
inhibitors to develop a highly-active anti-viral combination
therapy. On the other hand, these compounds are FDA-approved
drugs for different therapeutic indications (compound 1: antineo-
plastic agent; compound 2: inhibitor of thrombus formation;
compound 3: antineoplastic agent; compound 5: cholinergic and
parasympathomimetic agent, s; compound 6: antihypertensive
agent; compound 7: progestin agonist; and compound 8:
parasympatholytic agent), and valuable information regarding
pre-clinical tests (e.g. pharmacokinetic data) is available.
Future work will address resistance susceptibility and cross-
resistance patterns for the identified compounds, compared to
known NS3 inhibitors, by generating replicon systems containing
resistance-associated mutations.
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